DAPAGLIFLOZIN, PLACEBO
112930
Phase 3 small_molecule active
Quick answer
DAPAGLIFLOZIN, PLACEBO for Hypomagnesemia due to HNF1beta mutation is a Phase 3 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Hypomagnesemia due to HNF1beta mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active